{"meta":{"totalResults":12,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"carboplatin-paclitaxel regimen"},{"type":"LexicalVariant","name":"carboplatin-Taxol regimen"},{"type":"Synonym","name":"carbo-Tax regimen"},{"type":"Synonym","name":"CaT regimen"},{"type":"Synonym","name":"PC regimen"},{"type":"Synonym","name":"carboplatin-paclitaxel"},{"type":"Synonym","name":"carboplatin-Taxol"},{"type":"Synonym","name":"carboplatin/paclitaxel"},{"type":"Synonym","name":"paclitaxel-carboplatin"},{"type":"Synonym","name":"paclitaxel-carboplatin regimen"},{"type":"Synonym","name":"paclitaxel/carboplatin"},{"type":"Synonym","name":"paclitaxel/carboplatin regimen"},{"type":"Synonym","name":"TC regimen"}],"definition":{"html":"A regimen consisting of carboplatin and paclitaxel that may be used for the treatment of breast, kidney, cervical, vulvar, endometrial, ovarian, fallopian tube, primary peritoneal, head and neck, including cancer of the nasopharynx, esophageal and esophagogastric junction, and gastric cancers; non-small cell lung cancer (NSCLC); anaplastic carcinoma; anal, small bowel and non-urothelial and urothelial bladder cancer; salivary gland, malignant germ cell and malignant sex cord-stromal tumors; cutaneous and uveal melanoma; squamous cell skin cancer; thymomas and thymic carcinoma; occult primary adenocarcinoma or squamous cell carcinoma. Paclitaxel/carboplatin every 21 days regimen may be used for the treatment of esophageal and esophagogastric junction, and gastric cancers.","text":"A regimen consisting of carboplatin and paclitaxel that may be used for the treatment of breast, kidney, cervical, vulvar, endometrial, ovarian, fallopian tube, primary peritoneal, head and neck, including cancer of the nasopharynx, esophageal and esophagogastric junction, and gastric cancers; non-small cell lung cancer (NSCLC); anaplastic carcinoma; anal, small bowel and non-urothelial and urothelial bladder cancer; salivary gland, malignant germ cell and malignant sex cord-stromal tumors; cutaneous and uveal melanoma; squamous cell skin cancer; thymomas and thymic carcinoma; occult primary adenocarcinoma or squamous cell carcinoma. Paclitaxel/carboplatin every 21 days regimen may be used for the treatment of esophageal and esophagogastric junction, and gastric cancers."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/CARBOPLATIN-TAXOL","text":"CARBOPLATIN-TAXOL"},"nciConceptId":"C63402","nciConceptName":"Carboplatin/Paclitaxel Regimen","termId":657273,"name":"carboplatin/paclitaxel regimen","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"carboplatin-paclitaxel-regimen"},{"aliases":[{"type":"Synonym","name":"nanoparticle albumin-bound paclitaxel"},{"type":"Synonym","name":"nab paclitaxel"},{"type":"LexicalVariant","name":"paclitaxel nanoparticle albumin-bound"},{"type":"CodeName","name":"ABI-007"},{"type":"LexicalVariant","name":"ABI-007"},{"type":"USBrandName","name":"Abraxane"},{"type":"Synonym","name":"albumin-stabilized nanoparticle paclitaxel"},{"type":"Synonym","name":"nanoparticle paclitaxel"},{"type":"Synonym","name":"albumin-bound paclitaxel"},{"type":"Synonym","name":"protein-bound paclitaxel"},{"type":"CodeName","name":"ABI 007"},{"type":"Synonym","name":"paclitaxel albumin"},{"type":"Synonym","name":"paclitaxel protein-bound"}],"definition":{"html":"A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of the solvent Cremophor, thereby permitting the administration of larger doses of paclitaxel while avoiding the toxic effects associated with Cremophor.","text":"A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of the solvent Cremophor, thereby permitting the administration of larger doses of paclitaxel while avoiding the toxic effects associated with Cremophor."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/nanoparticlepaclitaxel","text":"Paclitaxel Albumin-stabilized Nanoparticle Formulation"},"nciConceptId":"C2688","nciConceptName":"Nab-paclitaxel","termId":38690,"name":"nab-paclitaxel","firstLetter":"n","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"nab-paclitaxel"},{"aliases":[{"type":"Synonym","name":"paclitaxel/HM30181A"},{"type":"Synonym","name":"paclitaxel-HM30181 methanesulfonate monohydrate"}],"definition":{"html":"A combination formulation composed of a capsule containing the taxane compound paclitaxel and a tablet containing the multidrug resistance (MDR) efflux pump P-glycoprotein (P-gp) inhibitor HM30181A, with potential antineoplastic activity. Upon oral administration of oraxol, the HM30181A moiety binds to and inhibits P-gp, which prevents P-gp-mediated efflux of paclitaxel, therefore enhancing its oral bioavailability. In turn, paclitaxel binds to and stabilizes microtubules, preventing their depolymerization, which results in the inhibition of cellular motility, mitosis, and replication. Altogether, this may result in greater intracellular concentration of paclitaxel, and enhanced cytotoxicity against tumor cells, when compared to the administration of paclitaxel alone.  P-gp, encoded by the MDR-1 gene, is a member of the ATP-binding cassette (ABC) superfamily of transmembrane transporters; it prevents the intestinal uptake and intracellular accumulation of various cytotoxic agents.","text":"A combination formulation composed of a capsule containing the taxane compound paclitaxel and a tablet containing the multidrug resistance (MDR) efflux pump P-glycoprotein (P-gp) inhibitor HM30181A, with potential antineoplastic activity. Upon oral administration of oraxol, the HM30181A moiety binds to and inhibits P-gp, which prevents P-gp-mediated efflux of paclitaxel, therefore enhancing its oral bioavailability. In turn, paclitaxel binds to and stabilizes microtubules, preventing their depolymerization, which results in the inhibition of cellular motility, mitosis, and replication. Altogether, this may result in greater intracellular concentration of paclitaxel, and enhanced cytotoxicity against tumor cells, when compared to the administration of paclitaxel alone.  P-gp, encoded by the MDR-1 gene, is a member of the ATP-binding cassette (ABC) superfamily of transmembrane transporters; it prevents the intestinal uptake and intracellular accumulation of various cytotoxic agents."},"drugInfoSummaryLink":null,"nciConceptId":"C112000","nciConceptName":"Oraxol","termId":754236,"name":"oraxol","firstLetter":"o","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"oraxol"},{"aliases":[{"type":"Abbreviation","name":"TAX"},{"type":"ObsoleteName","name":"Taxol"},{"type":"ChemicalStructureName","name":"5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine"},{"type":"ForeignBrandName","name":"Anzatax"},{"type":"ForeignBrandName","name":"Asotax"},{"type":"ForeignBrandName","name":"Bristaxol"},{"type":"ForeignBrandName","name":"Praxel"},{"type":"ForeignBrandName","name":"Taxol Konzentrat"},{"type":"ObsoleteName","name":"Onxal"},{"type":"ChemicalStructureName","name":"[2aR-[2a alpha,4beta,4a beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a alpha,12b alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester"},{"type":"INDCode","name":"22850"},{"type":"NSCNumber","name":"673089"},{"type":"NSCNumber","name":"125973"},{"type":"CASRegistryName","name":"33069-62-4"}],"definition":{"html":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).","text":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2)."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/paclitaxel","text":"Paclitaxel"},"nciConceptId":"C1411","nciConceptName":"Paclitaxel","termId":39762,"name":"paclitaxel","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"paclitaxel"},{"aliases":[{"type":"Synonym","name":"Oncofid-P-B"},{"type":"Synonym","name":"paclitaxel-hyaluronic acid"},{"type":"Abbreviation","name":"P-HA"},{"type":"Synonym","name":"paclitaxel/hyaluronic acid"}],"definition":{"html":"A water soluble, muco-adhesive co-formulation composed of the natural taxane paclitaxel conjugated to the naturally occurring proteoglycan hyaluronic acid, with potential antineoplastic activity. Upon intravesical administration of paclitaxel and hyaluronic acid, HA targets and binds to CD44 expressed on cancer cells. In turn, paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and inhibiting cellular motility, mitosis, and replication in CD44-expressing tumor cells. CD44, a transmembrane glycoprotein and HA receptor expressed in healthy tissue, is overexpressed in a variety of cancer cell types and plays a key role in tumor cell proliferation, migration and survival.","text":"A water soluble, muco-adhesive co-formulation composed of the natural taxane paclitaxel conjugated to the naturally occurring proteoglycan hyaluronic acid, with potential antineoplastic activity. Upon intravesical administration of paclitaxel and hyaluronic acid, HA targets and binds to CD44 expressed on cancer cells. In turn, paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and inhibiting cellular motility, mitosis, and replication in CD44-expressing tumor cells. CD44, a transmembrane glycoprotein and HA receptor expressed in healthy tissue, is overexpressed in a variety of cancer cell types and plays a key role in tumor cell proliferation, migration and survival."},"drugInfoSummaryLink":null,"nciConceptId":"C179565","nciConceptName":"Paclitaxel and Hyaluronic Acid","termId":804768,"name":"paclitaxel and hyaluronic acid","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"paclitaxel-and-hyaluronic-acid"},{"aliases":[{"type":"Abbreviation","name":"PICN"},{"type":"CodeName","name":"SPARC1023"},{"type":"CodeName","name":"SPARC1028"},{"type":"CodeName","name":"SPARC1210"}],"definition":{"html":"A nanoparticle-based injectable concentrate containing the water-insoluble taxane paclitaxel, with potential antineoplastic activity. Upon reconstitution and administration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Compared to paclitaxel alone, the nanodispersion-based formulation uses less toxic solvents and allows for administration of higher doses resulting in higher concentrations of paclitaxel at the tumor site, and an increased safety profile.","text":"A nanoparticle-based injectable concentrate containing the water-insoluble taxane paclitaxel, with potential antineoplastic activity. Upon reconstitution and administration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. Compared to paclitaxel alone, the nanodispersion-based formulation uses less toxic solvents and allows for administration of higher doses resulting in higher concentrations of paclitaxel at the tumor site, and an increased safety profile."},"drugInfoSummaryLink":null,"nciConceptId":"C96037","nciConceptName":"Paclitaxel Injection Concentrate for Nanodispersion","termId":696555,"name":"paclitaxel injection concentrate for nanodispersion","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"paclitaxel-injection-concentrate-for-nanodispersion"},{"aliases":[{"type":"USBrandName","name":"LEP-ETU"},{"type":"Synonym","name":"liposome-encapsulated paclitaxel"}],"definition":{"html":"A liposome-encapsulated formulation of paclitaxel, a taxoid compound extracted from the Pacific yew tree Taxus brevifolia, with antineoplastic property. Paclitaxel binds to tubulin and interferes with the assembly/disassembly dynamics of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis via inactivation of the apoptosis inhibitor, B-cell Leukemia 2 (Bcl-2) protein. Paclitaxel liposome formulation potentially enhances delivery of higher doses of paclitaxel to the target tissues and exhibits lower systemic toxicity.","text":"A liposome-encapsulated formulation of paclitaxel, a taxoid compound extracted from the Pacific yew tree Taxus brevifolia, with antineoplastic property. Paclitaxel binds to tubulin and interferes with the assembly/disassembly dynamics of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis via inactivation of the apoptosis inhibitor, B-cell Leukemia 2 (Bcl-2) protein. Paclitaxel liposome formulation potentially enhances delivery of higher doses of paclitaxel to the target tissues and exhibits lower systemic toxicity."},"drugInfoSummaryLink":null,"nciConceptId":"C2631","nciConceptName":"Paclitaxel Liposome","termId":38323,"name":"paclitaxel liposome","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"paclitaxel-liposome"},{"aliases":[{"type":"Synonym","name":"polyglutamate paclitaxel"},{"type":"CodeName","name":"CT-2103"},{"type":"USBrandName","name":"Xyotax"},{"type":"Abbreviation","name":"PG-TXL"},{"type":"Synonym","name":"paclitaxel-polyglutamate polymer"},{"type":"Synonym","name":"polyglutamic acid paclitaxel"},{"type":"Synonym","name":"Poly-L-Glutamic acid-Paclitaxel Conjugate"}],"definition":{"html":"The agent paclitaxel linked to a biodegradable, water-soluble polyglutamate polymer with antineoplastic properties. The polyglutamate residue increases the water solubility of paclitaxel and allows delivery of higher doses than those achievable with paclitaxel alone.  Paclitaxel promotes microtubule assembly and prevents microtubule depolymerization, thus interfering with normal mitosis.","text":"The agent paclitaxel linked to a biodegradable, water-soluble polyglutamate polymer with antineoplastic properties. The polyglutamate residue increases the water solubility of paclitaxel and allows delivery of higher doses than those achievable with paclitaxel alone.  Paclitaxel promotes microtubule assembly and prevents microtubule depolymerization, thus interfering with normal mitosis."},"drugInfoSummaryLink":null,"nciConceptId":"C1795","nciConceptName":"Paclitaxel Poliglumex","termId":38325,"name":"paclitaxel poliglumex","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"paclitaxel-poliglumex"},{"aliases":[{"type":"CodeName","name":"NANT008"},{"type":"LexicalVariant","name":"paclitaxel loaded polymeric micelle NANT-008"},{"type":"CodeName","name":"NANT 008"},{"type":"Synonym","name":"micellar nanoparticle-encapsulated NANT-008"},{"type":"Synonym","name":"paclitaxel-loaded micellar diblock copolymer NANT-008"},{"type":"USBrandName","name":"Cynviloq™"},{"type":"CodeName","name":"IG-001"},{"type":"USBrandName","name":"Genexol-PM"},{"type":"LexicalVariant","name":"Paclitaxel-Loaded Polymeric Micelle"},{"type":"CodeName","name":"NANT-008"},{"type":"Synonym","name":"nant-paclitaxel"}],"definition":{"html":"A nanoparticle-based formulation consisting of polymeric micelles encapsulating the taxane paclitaxel, with potential antineoplastic activity. Paclitaxel is covalently bound to polyethylene glycol (PEG)-based block copolymers which forms a micellar structure with an outer hydrophilic PEG shell surrounding the hydrophobic paclitaxel. Upon administration of the paclitaxel polymeric micelle formulation NANT-008, the nanoparticles are stable in the bloodstream and specifically accumulate in the tumor tissue. Due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, paclitaxel is released in the tumor environment. Paclitaxel binds to microtubules, promotes microtubule assembly, and prevents depolymerization, thus interfering with normal mitosis. Compared to the administration of paclitaxel alone, this formulation increases the solubility of paclitaxel, enhances its specific retention in cancer tissue, and increases its therapeutic effect, while decreasing its toxicity. In addition, the micellar formulation allows the delivery of higher doses of paclitaxel to target tissues while minimizing systemic toxicity.","text":"A nanoparticle-based formulation consisting of polymeric micelles encapsulating the taxane paclitaxel, with potential antineoplastic activity. Paclitaxel is covalently bound to polyethylene glycol (PEG)-based block copolymers which forms a micellar structure with an outer hydrophilic PEG shell surrounding the hydrophobic paclitaxel. Upon administration of the paclitaxel polymeric micelle formulation NANT-008, the nanoparticles are stable in the bloodstream and specifically accumulate in the tumor tissue. Due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, paclitaxel is released in the tumor environment. Paclitaxel binds to microtubules, promotes microtubule assembly, and prevents depolymerization, thus interfering with normal mitosis. Compared to the administration of paclitaxel alone, this formulation increases the solubility of paclitaxel, enhances its specific retention in cancer tissue, and increases its therapeutic effect, while decreasing its toxicity. In addition, the micellar formulation allows the delivery of higher doses of paclitaxel to target tissues while minimizing systemic toxicity."},"drugInfoSummaryLink":null,"nciConceptId":"C148531","nciConceptName":"Paclitaxel Polymeric Micelle Formulation NANT-008","termId":434427,"name":"paclitaxel polymeric micelle formulation NANT-008","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"paclitaxel-polymeric-micelle-formulation-nant-008"},{"aliases":[{"type":"CodeName","name":"S-8184"},{"type":"USBrandName","name":"Tocosol Paclitaxel"}],"definition":{"html":"A cremophor-free, P-glycoprotein-inhibiting, vitamin E-based emulsion particle formulation of paclitaxel with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). The vitamin-E based emulsion allows bolus infusion without steroid premedication and may diminish hypersensitivity reactions; tumor tissue may be passively targeted due to preferential deposition of emulsion particles while an emulsion formulation component inhibits the P-glycoprotein drug efflux pump.","text":"A cremophor-free, P-glycoprotein-inhibiting, vitamin E-based emulsion particle formulation of paclitaxel with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). The vitamin-E based emulsion allows bolus infusion without steroid premedication and may diminish hypersensitivity reactions; tumor tissue may be passively targeted due to preferential deposition of emulsion particles while an emulsion formulation component inhibits the P-glycoprotein drug efflux pump."},"drugInfoSummaryLink":null,"nciConceptId":"C61079","nciConceptName":"Paclitaxel Vitamin E-Based Emulsion","termId":474798,"name":"paclitaxel vitamin E-based emulsion formulation","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"paclitaxel-vitamin-e-based-emulsion"},{"aliases":[{"type":"CodeName","name":"MB1707"},{"type":"CodeName","name":"MB 1707"},{"type":"CodeName","name":"MB-1707"},{"type":"Synonym","name":"paclitaxel-conjugated CXC chemokine receptor 4 antagonist MB1707"},{"type":"Synonym","name":"PDC MB1707"},{"type":"Synonym","name":"peptide-drug conjugate MB1707"}],"definition":{"html":"A peptide-drug conjugate (PDC) of paclitaxel with an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon administration of paclitaxel-conjugated CXCR4 peptide antagonist MB1707, the CXCR4 inhibitor moiety binds to the chemokine receptor CXCR4 expressed on tumor cells, thereby preventing CXCR4 binding to its ligand, stromal derived factor-1 (SDF-1), and subsequent receptor activation. This may result in decreased tumor cell proliferation and migration. In addition, paclitaxel binds to tubulin inside CXCR4-expressing tumor cells and inhibits the disassembly-assembly dynamics of microtubules, resulting in cell cycle arrest and cell death. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types. By targeting CXCR4-expressing tumor cells specifically, paclitaxel's efficacy is increased while minimizing systemic toxiciy.\n","text":"A peptide-drug conjugate (PDC) of paclitaxel with an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon administration of paclitaxel-conjugated CXCR4 peptide antagonist MB1707, the CXCR4 inhibitor moiety binds to the chemokine receptor CXCR4 expressed on tumor cells, thereby preventing CXCR4 binding to its ligand, stromal derived factor-1 (SDF-1), and subsequent receptor activation. This may result in decreased tumor cell proliferation and migration. In addition, paclitaxel binds to tubulin inside CXCR4-expressing tumor cells and inhibits the disassembly-assembly dynamics of microtubules, resulting in cell cycle arrest and cell death. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types. By targeting CXCR4-expressing tumor cells specifically, paclitaxel's efficacy is increased while minimizing systemic toxiciy.\n"},"drugInfoSummaryLink":null,"nciConceptId":"C189826","nciConceptName":"Paclitaxel-conjugated CXCR4 Peptide Antagonist MB1707","termId":810387,"name":"paclitaxel-conjugated CXCR4 peptide antagonist MB1707","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"paclitaxel-conjugated-cxcr4-peptide-antagonist-mb1707"},{"aliases":[{"type":"Synonym","name":"nanoencapsulated paclitaxel FID-007"},{"type":"Synonym","name":"paclitaxel in polyethyloxazoline polymer"},{"type":"CodeName","name":"FID007"},{"type":"CodeName","name":"FID 007"}],"definition":{"html":"A nanoparticle-based formulation composed of the poorly water-soluble paclitaxel encapsulated within branched polymers composed of polyethyloxazoline (PEOX), with potential antineoplastic activity. Upon injection of the PEOX-based polymer encapsulated paclitaxel FID-007, the nanoparticles accumulate at the tumor site, due to the unique characteristics of the tumor vasculature, while avoiding normal, healthy tissue. Once the paclitaxel is released, it binds to tubulin inside tumor cells and inhibits the disassembly-assembly dynamics of microtubules, resulting in cell cycle arrest and cell death. Compared to the administration of paclitaxel alone, this formulation increases paclitaxel's solubility and enhances its tumor tissue penetration and efficacy, while avoiding systemic exposure, which minimizes its toxicity.","text":"A nanoparticle-based formulation composed of the poorly water-soluble paclitaxel encapsulated within branched polymers composed of polyethyloxazoline (PEOX), with potential antineoplastic activity. Upon injection of the PEOX-based polymer encapsulated paclitaxel FID-007, the nanoparticles accumulate at the tumor site, due to the unique characteristics of the tumor vasculature, while avoiding normal, healthy tissue. Once the paclitaxel is released, it binds to tubulin inside tumor cells and inhibits the disassembly-assembly dynamics of microtubules, resulting in cell cycle arrest and cell death. Compared to the administration of paclitaxel alone, this formulation increases paclitaxel's solubility and enhances its tumor tissue penetration and efficacy, while avoiding systemic exposure, which minimizes its toxicity."},"drugInfoSummaryLink":null,"nciConceptId":"C148635","nciConceptName":"PEOX-based Polymer Encapsulated Paclitaxel FID-007","termId":796978,"name":"PEOX-based polymer encapsulated paclitaxel FID-007","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"peox-based-polymer-encapsulated-paclitaxel-fid-007"}],"links":null}